A Phase 1b Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine ( Rituximab) Gemcitabine Lenalidomide or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy
Brief description of study
If you have been diagnosed with relapsed and refractory advanced Non-Hodgkin Lymphoma, you may qualify to participate in a clinical trial. The main goal of this Phase 1b study is to determine the most effective dose of the experimental drug, TAK-659, when administered with each of the combination partners (bendamustine, bendamustine +rituximab, gemcitabine, lenalidomide, and ibrutinib). In addidtion, we would like to study blood samples to understand how much TAK-659 is in the blood over time, which is known as pharmacokinetic (PK) testing.
Clinical Study Identifier: s16-02305
ClinicalTrials.gov Identifier: NCTs16-02305
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
